International AIDS Society Newsletter, no. 21

INTERNATIONAL
AIDS SOCIETY

ing sites from different countries of the North
and the South has already successfully transmitted drug resistance surveillance information to a central data center.
Future
The precious opportunity to extend the benefits of ART to resource limited settings calls
for us to monitor and contain drug resistance
based on the lessons the developed world has
already learned. If we do not begin with a serious effort now, it may be an insurmountable
task to catch up later. Efforts to increase drug
access and contain drug resistance need to go
hand-in-hand with the global ARV treatment
programs. It is our hope that the WHO/IAS
Surveillance Program will create synergistic
linkages between the North and South, inform
policy makers and result in the better treatments for HIV infected persons. We welcome
your participation in this effort.
REFERENCES
I. Hammer S GD, Havlir D, Mofenson L, Van Beek I, Vella S.,
Chebet K, Dybul M, Giaquinto C, Katabira E, Katlama C,
Kazatchkine M, MalkinjE, McIntyre], M'Boup S,
MokhhbatJ, MukherjeeJ,. Phanupak P. Schechter M, de
Avila Vittoria M. Scaling Up Antiretroviral Therapy in
Resource Limited Settings: Guidelines for a Public Health
Approach: The World Health Organization, 2002.
http://uwww: who.int/HIVAIDS/HIVAIDSCare/ARV
Draft April 2002.pdf
2. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243 (4899): 1731-4.. 1989.
3. CoffinJM. HIV population dynamics in vivo: implications
for genetic variation, pathogenesis. and therapy. Science 267
(5197): 483-9., 1995.
4. Ho DD, Neumann AU, Perelson AS. Chen W LeonardJM.,
Markowitz M. Rapid turnover of plasma virions and CD4
lymphocytes in HIV-1 infection. Nature 373 (6510): 123 -6., 1995.
5. Najera I. Richman DD, Olivares I, RojasJM, Peinado
MA, Perucho M, Najera R, Lopez-Galindez C. Natural
occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS
Res Hum Retroviruses 10 (11): 1479-88.. 1994.
6. Richman DD, Havlir D, Corbeil]J, Looney D, Ignacio C.
Spector SA, SullivanJ]. Cheeseman S. Barringer K. Pauletti
D. et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy.] Virol 68 (3):
1660-6., 1994.

7. Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas],
Staszewski S.]Johnson M, Hill AM, Pearce G, McDade H.
Safety and efficacy of lamivudine-zidovudine combination
therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine
European HIV Working Group.Jama 276 (2): 118-25..,
1996.
8. Delta Coordinating Committee. Delta: a randomised doubleblind controlled trial comparing combinations of zidovudine
plus didanosine or zalcitabine with zidovudine alone in HIVinfected individuals. Lancet 348 (9023): 283-91, 1996.
9. Paterson DL, Swindells S, MohrJ, Brester M. Vergis EN.,
Squier C. Wagener MM, Singh N. Adherence to protease
inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133 (1): 21-30., 2000.
10. Kantor R. Fessel WJ,]. Zolopa AR. Israelski D. Shulman N,
MontoyaJG, Harbour M, SchapiroJM, Shafer RW.
Evolution of Primary Protease Inhibitor Resistance Mutations
during Protease Inhibitor Salvage Therapy. Antimicrob
Agents Chemother 46 (4): 1086-92.. 2002.
11. Erice A. Mayers DL, Strike DG, Sannerud K], McCutchan
FE, Henry K. Balfour HH,Jr. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus
type 1. N EnglJMed328 (16): 1163-5., 1993.
12. Johnson VA. Petropoulos C], Woods CR, HazelwoodJD,
Parkin NT Hamilton CD. Fiscus SA. Vertical transmission
of multidrug-resistant human immunodeficiency virus type 1
(HIV-1) and continued evolution of drug resistance in an
HIV-1-infected infant.] JInfect Dis 183 (11): 1688-93.,
2001.
13. Little SJ RJ,]. Daar ES, Markowitz M, Collier AC, Koup
RA, Conuay B, Saag MS, Connick E. Holte S, Corey L,
Keiser PH. Mwatha A. Dawson K, WhitcombJM,
Hellmann NS, Richman DD. Antiretroviral Drug
Susceptibility and Response to Initial Therapy Among
Recently HIV-Infected Subjects in North America. In: 8th
Conference on Retroviruses and Opportunistic Infections,
February 4-8, Chicago, IL, 2001.
14. Harzic M. Pellegrin I, Deveau C, Chaix ML, Dubeaux B,
Garrigue I, Ngo N, Rouzioux C, Goujard C, Hoen B, Sereni
D, DefraissyjE Meyer L. Genotypic drug resistance during
HIV-1 primary infection in France (1996-1999):frequency
and response to treatment. Aids 16 (5): 793-6.. 2002.
15. Yerly S. Vora S, Rizzardi P, Chave]JP, Vernazza PL, Flepp
M, Telenti A, Battegay M, Veuthey AL, BruJP, Rickenbach
M. Hirschel B. Perrin L. Acute HIV infection: impact on the
spread of HIV and transmission of drug resistance. Aids 15
(17): 2287-92., 2001.
16. Richman DD BS, Morton S, Chien S, Wrin T, Dawson K,
Hellmann N. The prevalence of antiretroviral drug resistance
in the United States. In: 41st International Conference on
Antimicrobial Agents and Chemotherapy, December 18.
Chicago, IL. 2001.
17. Rosenbach KA. Allison R. NadlerJP. Daily dosing of highly
active antiretroviral therapy. Clin Infect Dis 34 (5): 686 -92.. 2002.
18. Hirsch MS. Brun-Vezinet F D'Aquila RT Hammer SM.
Johnson VA, Kuritzkes DR, Loveday C, Mellors]W Clotet
B, Conuay B, Demeter LM. Vella S.Jacobsen DM, Richman
DD. Antiretroviral drug resistance testing in adult HIV-1
infection: recommendations of an International AIDS SocietyUSA Panel.Jama 283 (18): 2417-26., 2000.

19. Carpenter CC, Cooper DA, Fischl MA, Gatell]M,
Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM,
Katzenstein DA, MontanerJS, Richman DD, Saag MS,
Schechter M, Schooley RT Thompson MA, Vella S, Yeni PG,
Volberding PA. Antiretroviral therapy in adults: updated
recommendations of the International AIDS Society-USA
Panel.Jama 283 (3): 381-90.. 2000.
20. Adje C, Cheingsong R. Roels TH, Maurice C. Djomand G.
Verbiest W Hertogs K, Larder B. Monga B. Peeters M,
Eholie S, Bissagene E, Coulibaly M. Respess R. Wiktor SZ.
Chorba T Nkengasong]N. High prevalence of genotypic and
phenotypic HIV-1 drug-resistant strains among patients
receiving antiretroviral therapy in Abidjan, Cote d'Ivoire.]J
Acquir Immune Defic Syndr 26 (5): 501-6., 2001.
21. Eshleman SH, Mracna M, Guay LA, Deseyve M,
Cunningham S, Mirochnick M. Musoke P Fleming T, Glenn
Fowler M, Mofenson LM, Mmiro F, ]ackson]B. Selection
and fading of resistance mutations in women and infants
receiving nevirapine to prevent HIV-1 vertical transmission
(HIVNET 012). Aids 15 (15): 1951-7., 2001.
22. Caride E, Brindeiro R, Hertogs K, Larder B, Dehertogh P,
Machado E, de Sa CA, Eyer-Silva WA, Sion FS, Passioni
LE MenezesJA, Calazans AR, Tanuri A. Drug-resistant
reverse transcriptase genotyping and phenotyping of B and
non-B subtypes (F and A) of human immunodeficiency virus
type I found in Brazilian patients failing HAART Virology
275 (1): 107-15., 2000.
23. Ungsedhapand C, Kroon ED, Suwanagool S. Ruxrungtham
K, Yimsuan N, Sonjai A, Ubolyam S, Buranapraditkun S.
Tiengrim S, Pakker N, Kunanusont C, Lange]M, Cooper
DA, Phanuphak P A randomized, open-label, comparative
trial of zidovudine plus lamivudine versus zidovudine plus
lamivudine plus didanosine in antiretroviral-naive HIV-1 -infected Thai patients.]J Acquir Immune Defic Syndr 27 (2):
116-23.. 2001.
24. Quinones-Mateu ME, Soriano V Domingo E, MenendezArias L. Characterization of the reverse transcriptase of a
human immunodeficiency virus type 1 group 0 isolate.
Virology 236 (2): 364-73., 1997.
25. Pieniazek D, Rayfield M, Hu DJ, Nkengasong, Wiktor
SZ, Downing R, Biryahwaho B, Mastro T, Tanuri A,
Soriano V Lal R, Dondero T Protease sequences from HIV-1
group M subtypes A-H reveal distinct amino acid mutation
patterns associated with protease resistance in protease
inhibitor-naive individuals uworldwide. HIV Variant
Working Group. Aids 14 (11): 1489-95., 2000.
26. Becker-Pergola G, Kataaha P, Johnston-Dow L. Fung S,
Jackson]B. Eshleman SH. Analysis of HIV type 1 protease
and reverse transcriptase in antiretroviral drug-naive
Ugandan adults. AIDS Res Hum Retroviruses 16 (8): 807 -13., 2000.